JP2025526402A5 - - Google Patents

Info

Publication number
JP2025526402A5
JP2025526402A5 JP2025504350A JP2025504350A JP2025526402A5 JP 2025526402 A5 JP2025526402 A5 JP 2025526402A5 JP 2025504350 A JP2025504350 A JP 2025504350A JP 2025504350 A JP2025504350 A JP 2025504350A JP 2025526402 A5 JP2025526402 A5 JP 2025526402A5
Authority
JP
Japan
Prior art keywords
approximately
weeks
administered
doses
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025504350A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025526402A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2023/071103 external-priority patent/WO2024026395A1/en
Publication of JP2025526402A publication Critical patent/JP2025526402A/ja
Publication of JP2025526402A5 publication Critical patent/JP2025526402A5/ja
Pending legal-status Critical Current

Links

JP2025504350A 2022-07-27 2023-07-27 潰瘍性大腸炎及びクローン病治療のための抗tl1a抗体 Pending JP2025526402A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263369591P 2022-07-27 2022-07-27
US63/369,591 2022-07-27
US202263387786P 2022-12-16 2022-12-16
US63/387,786 2022-12-16
PCT/US2023/071103 WO2024026395A1 (en) 2022-07-27 2023-07-27 Anti-tl1a antibodies for the treatment of ulcerative colitis and crohn's disease

Publications (2)

Publication Number Publication Date
JP2025526402A JP2025526402A (ja) 2025-08-13
JP2025526402A5 true JP2025526402A5 (cg-RX-API-DMAC7.html) 2025-09-05

Family

ID=87747839

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2025504350A Pending JP2025526402A (ja) 2022-07-27 2023-07-27 潰瘍性大腸炎及びクローン病治療のための抗tl1a抗体

Country Status (12)

Country Link
US (1) US20250270336A1 (cg-RX-API-DMAC7.html)
EP (1) EP4562040A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025526402A (cg-RX-API-DMAC7.html)
KR (1) KR20250044336A (cg-RX-API-DMAC7.html)
CN (1) CN119894931A (cg-RX-API-DMAC7.html)
AU (1) AU2023314783A1 (cg-RX-API-DMAC7.html)
CA (1) CA3262839A1 (cg-RX-API-DMAC7.html)
CL (1) CL2025000202A1 (cg-RX-API-DMAC7.html)
IL (1) IL318428A (cg-RX-API-DMAC7.html)
MA (1) MA71621A (cg-RX-API-DMAC7.html)
MX (1) MX2025001041A (cg-RX-API-DMAC7.html)
WO (1) WO2024026395A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL325993A (en) 2023-08-11 2026-03-01 Paragon Therapeutics Inc TL1A binding proteins and methods of use

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20040014194A1 (en) 2002-03-27 2004-01-22 Schering Corporation Beta-secretase crystals and methods for preparing and using the same
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP3495389A1 (en) 2011-09-30 2019-06-12 Teva Pharmaceuticals Australia Pty Ltd Antibodies against tl1a and uses thereof
CN105814081B (zh) 2013-11-13 2021-02-02 辉瑞大药厂 肿瘤坏死因子样配体1a特异性抗体及其组合物和用途
TWI703158B (zh) 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
PT3774897T (pt) * 2018-04-30 2023-11-10 Cedars Sinai Medical Center Métodos e sistemas para seleção e tratamento de pacientes com doenças inflamatórias
EP3969621A4 (en) * 2019-05-14 2023-01-25 Prometheus Biosciences, Inc. TL1A PATIENT SELECTION METHODS, SYSTEMS AND DEVICES
WO2021034639A1 (en) * 2019-08-16 2021-02-25 Regeneron Pharmaceuticals, Inc. High concentration anti-c5 formulations
EP4171632A2 (en) 2020-06-26 2023-05-03 Pfizer Inc. Methods of treating inflammatory bowel disease with tl1a antibodies

Similar Documents

Publication Publication Date Title
JP6283665B2 (ja) Gd2陽性癌を治療するための方法
JP2014533279A5 (cg-RX-API-DMAC7.html)
JP2013166765A5 (cg-RX-API-DMAC7.html)
JP2008507555A5 (cg-RX-API-DMAC7.html)
JP2021130668A (ja) 多発性骨髄腫(mm)の処置
JP2022531408A5 (cg-RX-API-DMAC7.html)
JP2023542093A (ja) 抗腫瘍治療におけるチアウラニブと免疫チェックポイント阻害剤との組み合わせの使用
WO2023217268A1 (zh) 抗tim-3抗体与抗pd-1抗体的药物组合
JP2020521777A (ja) 抗cd19抗体とベネトクラクスとの組み合わせ治療のための治療パラダイム
US20250075007A1 (en) Treatment of Al Amyloidosis with the Combination of Monoclonal Antibodies Agains Immunoglobulin Light Chains and the CD38 Cell Membrane Molecule on Antibody-Producing And Other Immune Cells
US20230058779A1 (en) Combination cancer treatment using a pd-1 antagonist, an ilt4 antagonist, and lenvatinib or salts thereof
JP2025515092A5 (cg-RX-API-DMAC7.html)
TWI870592B (zh) 使用免疫檢查點抑制劑抗體治療癌症之方法和組合
CN121079314A (zh) 用于组合疗法的方法和组合物
CN115957321A (zh) 一种抗her2抗体在制备治疗癌症的药物中的用途
JP2024521105A5 (cg-RX-API-DMAC7.html)
JP2022514561A5 (cg-RX-API-DMAC7.html)
CN112955148B (zh) Cdk4/6抑制剂联合免疫治疗在制备治疗淋巴瘤的药物中的用途
WO2021213523A1 (zh) 抗pd-1抗体和抗ctla-4抗体的组合在预防或治疗癌症中的用途
CN117815387A (zh) Cdk4/6抑制剂和抗pd-l1抗体的联用药物组合物
WO2023174408A1 (zh) 抗tim-3抗体与抗pd-l1抗体的药物组合
TW202428254A (zh) 用於治療晚期實性瘤之組成物及方法
JP2024532744A (ja) T1gitアンタゴニスト、pd-1アンタゴニスト、及び(1又は複数の)化学療法剤を含む治療的組合せ
JP2021528399A5 (cg-RX-API-DMAC7.html)
JP2024531220A (ja) Tigitアンタゴニスト、pd-1アンタゴニスト、及びレンバチニブを含む治療薬の組み合わせ